Eventide Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Eventide Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-75,000	Closed	-$5.78M	–	136
2018 Q3	$5.78M	Sell	75,000 -103,000	-58%	-$8.29M	0.21%	98
2018 Q2	$15M	Hold	178,000	–	–	0.62%	60
2018 Q1	$14.6M	Sell	178,000 -36,000	-17%	-$2.78M	0.68%	55
2017 Q4	$12.2M	Hold	214,000	–	–	0.64%	56
2017 Q3	$14.3M	Sell	214,000 -86,800	-29%	-$5.21M	0.81%	47
2017 Q2	$15.5M	Hold	300,800	–	–	0.96%	44
2017 Q1	$17.6M	Hold	300,800	–	–	1.16%	38
2016 Q4	$12.6M	Hold	300,800	–	–	0.82%	46
2016 Q3	$15.9M	Hold	300,800	–	–	0.97%	38
2016 Q2	$12.6M	Hold	300,800	–	–	0.77%	47
2016 Q1	$12.2M	Hold	300,800	–	–	0.68%	49
2015 Q4	$19.5M	Buy	300,800 +55,900	+23%	+$3.67M	0.98%	42
2015 Q3	$17.3M	Buy	244,900 +78,700	+47%	+$7.69M	1%	41
2015 Q2	$18.5M	Hold	166,200	–	–	1%	42
2015 Q1	$15.7M	Sell	166,200 -92,000	-36%	-$10.3M	1.18%	35
2014 Q4	$28.9M	Sell	258,200 -173,400	-40%	-$15.5M	3.16%	2
2014 Q3	$26.5M	Sell	431,600 -58,900	-12%	-$2.54M	3.7%	2
2014 Q2	$22.5M	Buy	490,500 +36,300	+8%	+$1.48M	3.06%	1
2014 Q1	$17.8M	Buy	454,200 +245,400	+118%	+$8.21M	2.76%	1
2013 Q4	$5M	Buy	+208,800	New	+$4.76M	1.54%	35

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Eventide Asset Management's AGIO Position: Q4 2018 in Review

Eventide Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 75,000 shares — an estimated $5.78M sold.

Eventide Asset Management first reported a position in AGIO in Q4 2013 and held it in 20 quarters. The position peaked at $28.9M in Q4 2014. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

Eventide Asset Management reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Eventide Asset Management sold 75,000 Agios Pharmaceuticals shares in Q4 2018, an estimated $5.78M.
Eventide Asset Management first reported a position in Agios Pharmaceuticals in Q4 2013 and held it in 20 quarters.
Eventide Asset Management's Agios Pharmaceuticals position peaked at $28.9M in Q4 2014.
196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on Eventide Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.